Anti-Inflammatory Drugs — NSAIDs, Corticosteroids, and Gout

Correct Answer

B) Proton pump inhibitor

Rationale

Proton pump inhibitors are the preferred gastroprotective co-therapy for patients who require nonsteroidal anti-inflammatory drugs and have risk factors for gastrointestinal complications. They reduce the relative risk of nonsteroidal anti-inflammatory drug-associated endoscopic ulcers by approximately 75% and are preferred over misoprostol because of substantially better tolerability. Histamine H1 receptor antagonists are antihistamines used for allergic conditions, mineralocorticoid receptor antagonists are potassium-sparing diuretics, and phosphodiesterase inhibitors are used for heart failure and other indications.

Correct Answer

C) Naproxen

Rationale

Among commonly used nonselective nonsteroidal anti-inflammatory drugs, naproxen is classified as carrying the most favorable cardiovascular risk profile. Its long half-life produces sustained cyclooxygenase-1 inhibition that confers a partial antiplatelet effect, partially offsetting the prothrombotic tendency shared by other agents in the class. High-dose diclofenac and high-dose ibuprofen carry cardiovascular risk comparable to selective cyclooxygenase-2 inhibitors. Naproxen is the preferred nonsteroidal anti-inflammatory drug when one is required in patients with cardiovascular risk factors.

Correct Answer

A) Diclofenac

Rationale

Diclofenac is available as a topical gel formulation (1% and 1.5% concentrations) indicated for localized joint pain such as hand and knee osteoarthritis. Topical application delivers drug directly to the target tissue with minimal systemic absorption, avoiding most of the gastrointestinal, cardiovascular, and renal risks associated with oral nonsteroidal anti-inflammatory drug therapy. Indomethacin, ketorolac, and celecoxib are not available in topical gel formulations for this indication.

Correct Answer

D) Warfarin

Rationale

Warfarin is classified as a vitamin K antagonist anticoagulant. It inhibits the hepatic enzyme vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby impairing the synthesis of clotting factors II, VII, IX, and X. Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1, clopidogrel is an antiplatelet agent that blocks adenosine diphosphate receptors on platelets, and heparin is a parenteral anticoagulant that potentiates antithrombin III activity.

Correct Answer

B) Methotrexate

Rationale

Methotrexate is classified as both a disease-modifying antirheumatic drug and an antimetabolite. It inhibits dihydrofolate reductase, impairing folate metabolism and thereby reducing rapidly dividing cell populations involved in inflammatory and immune responses. At low weekly doses used in rheumatoid arthritis and psoriasis it functions as a disease-modifying antirheumatic drug; at higher doses used in oncology it functions as a cytotoxic antimetabolite. Naproxen is a nonselective nonsteroidal anti-inflammatory drug, warfarin is a vitamin K antagonist anticoagulant, and misoprostol is a synthetic prostaglandin E1 analogue.

Correct Answer

C) Piroxicam

Rationale

Piroxicam is classified as a long-acting nonselective nonsteroidal anti-inflammatory drug with a plasma half-life of 30 to 86 hours, allowing once-daily dosing. Its long half-life also means that platelet cyclooxygenase-1 inhibition may persist for two to four days after the last dose, which is relevant for perioperative management. Ibuprofen and ketorolac are short-acting agents with half-lives of hours. Diclofenac is a cyclooxygenase-2 preferential agent with an intermediate half-life.

Correct Answer

D) Nonsteroidal anti-inflammatory drugs deplete the cytoprotective prostaglandins that maintain mucosal defense, while corticosteroids independently impair mucosal repair by inhibiting fibroblast proliferation and epithelial regeneration

Rationale

Nonsteroidal anti-inflammatory drugs produce gastrointestinal mucosal injury by suppressing cyclooxygenase-1-dependent prostaglandins that normally maintain mucosal blood flow, stimulate mucus and bicarbonate secretion, and inhibit acid secretion. Corticosteroids do not inhibit cyclooxygenase directly, but they independently compromise mucosal healing by impairing fibroblast proliferation and the epithelial repair mechanisms that normally limit ulcer progression. When both drug classes are used together, prostaglandin-dependent defense is lost and the capacity for mucosal repair is simultaneously impaired, producing a risk of gastrointestinal bleeding approximately tenfold greater than either agent alone. Proton pump inhibitor co-prescription is mandatory when these drug classes are combined.

Correct Answer

A) Naproxen's long half-life produces sustained cyclooxygenase-1 inhibition in platelets, providing a partial antiplatelet effect that partially counteracts the prothrombotic tendency common to nonsteroidal anti-inflammatory drugs

Rationale

Unlike selective cyclooxygenase-2 inhibitors, which suppress endothelial prostacyclin while leaving platelet thromboxane A2 intact, naproxen inhibits both cyclooxygenase isoforms. Its long half-life of 12 to 17 hours produces sustained cyclooxygenase-1 inhibition in platelets throughout the dosing interval, generating a partial antiplatelet effect that partially offsets the prothrombotic tendency produced by reduced endothelial prostacyclin. This is the pharmacological basis for naproxen being the preferred nonsteroidal anti-inflammatory drug in patients with cardiovascular risk factors. Naproxen does not selectively spare cyclooxygenase-1 in platelets, does not inhibit adenosine diphosphate receptors, and has a long rather than short half-life.

Correct Answer

C) Nonsteroidal anti-inflammatory drugs simultaneously impair platelet function through cyclooxygenase-1 inhibition and create bleeding-prone gastric erosions through prostaglandin depletion, while anticoagulants prevent clot formation at any mucosal bleeding site that develops

Rationale

This combination creates additive risk through two parallel mechanisms. Nonsteroidal anti-inflammatory drugs suppress cyclooxygenase-1 in platelets, impairing thromboxane A2-dependent platelet aggregation and reducing the platelet plug that would normally limit bleeding. Simultaneously, nonsteroidal anti-inflammatory drugs deplete the cytoprotective prostaglandins that maintain gastric mucosal integrity, creating erosions and ulcers that are prone to bleed. Anticoagulants then prevent fibrin clot formation at these mucosal bleeding sites, converting small bleeds into potentially life-threatening hemorrhage. When this combination cannot be avoided, proton pump inhibitor co-therapy and the shortest necessary nonsteroidal anti-inflammatory drug duration are required.

Correct Answer

B) Naproxen inhibits platelet cyclooxygenase-1 reversibly, so platelet function recovers as plasma drug concentrations fall, while aspirin permanently acetylates cyclooxygenase-1 in platelets that cannot replace the inactivated enzyme

Rationale

Non-aspirin nonsteroidal anti-inflammatory drugs inhibit platelet cyclooxygenase-1 reversibly — the enzyme regains activity as drug concentrations fall below the inhibitory threshold. Because naproxen has a half-life of 12 to 17 hours, platelet thromboxane A2 synthesis recovers within approximately three to five days after the last dose. Aspirin, by contrast, permanently acetylates cyclooxygenase-1 in platelets. Because platelets are anucleate and cannot synthesize new enzyme, recovery requires 7 to 10 days for the platelet pool to renew through normal platelet turnover. The mechanism difference — reversible versus irreversible cyclooxygenase-1 inhibition — determines the perioperative hold duration.

Correct Answer

A) Selective serotonin reuptake inhibitors deplete platelet serotonin by blocking its reuptake into platelets, impairing serotonin-dependent platelet activation, while nonsteroidal anti-inflammatory drugs simultaneously suppress thromboxane A2-dependent platelet activation through cyclooxygenase-1 inhibition

Rationale

Platelets depend on two independent pathways for activation: thromboxane A2, generated by cyclooxygenase-1, and serotonin, stored in dense granules and released on platelet activation. Platelets cannot synthesize serotonin — they acquire it entirely from the bloodstream via the serotonin transporter. Selective serotonin reuptake inhibitors block this transporter, depleting platelet serotonin stores over weeks of chronic use. Nonsteroidal anti-inflammatory drugs suppress the thromboxane A2 pathway through cyclooxygenase-1 inhibition. Together, these two drugs suppress both major serotonin-independent and thromboxane A2-dependent activation pathways, producing platelet dysfunction more severe than either drug alone. Proton pump inhibitor co-prescription is appropriate when a patient requires both a selective serotonin reuptake inhibitor and chronic nonsteroidal anti-inflammatory drug therapy.

Correct Answer

D) Prostaglandin E2 maintains fetal ductus arteriosus patency through receptor-mediated vasodilation; nonsteroidal anti-inflammatory drug-mediated cyclooxygenase inhibition suppresses prostaglandin E2 and causes premature ductal closure, resulting in fetal right ventricular pressure overload

Rationale

The fetal ductus arteriosus — the vascular shunt connecting the pulmonary artery to the aorta that allows blood to bypass the fetal lungs — is maintained open by prostaglandin E2 acting on prostaglandin E receptors in the ductal wall. When nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase from approximately 28 weeks of gestation onward, prostaglandin E2 synthesis is suppressed and the ductus arteriosus can constrict prematurely. Premature ductal closure forces the fetal right ventricle to pump against increased resistance, potentially causing right ventricular hypertrophy, tricuspid regurgitation, and fetal hydrops. Nonsteroidal anti-inflammatory drugs are therefore strongly contraindicated after 28 weeks of gestation. Acetaminophen is the preferred analgesic throughout pregnancy.

Correct Answer

B) Nonsteroidal anti-inflammatory drugs compete with methotrexate for renal tubular secretion transporters and reduce renal blood flow by suppressing renal prostaglandins, impairing methotrexate excretion and raising its plasma concentration to toxic levels

Rationale

Methotrexate at oncology doses is excreted renally through two mechanisms: glomerular filtration and active tubular secretion via organic anion transporters. Nonsteroidal anti-inflammatory drugs share these tubular secretion transporters and compete with methotrexate for excretion, slowing its renal clearance. Additionally, nonsteroidal anti-inflammatory drug-mediated suppression of renal prostaglandins reduces renal blood flow, further impairing methotrexate elimination. The resulting prolonged elevation of methotrexate plasma concentrations can cause severe myelosuppression and mucositis. At the lower weekly doses used for rheumatoid arthritis, the interaction is less acute, but monitoring remains appropriate.

Correct Answer

C) Nonsteroidal anti-inflammatory drugs suppress prostaglandin synthesis in the fetal kidney, reducing fetal urine output and leading to decreased amniotic fluid volume

Rationale

Fetal urine is the primary source of amniotic fluid from the second trimester onward. Renal prostaglandins play an important role in regulating fetal renal blood flow and urine production. When nonsteroidal anti-inflammatory drugs suppress prostaglandin synthesis in the fetal kidney, fetal urine output falls, leading to oligohydramnios — a reduction in amniotic fluid volume. Oligohydramnios can cause limb contractures, delayed lung development, and fetal growth restriction with prolonged exposure. The Food and Drug Administration recommends ultrasound monitoring of amniotic fluid volume if nonsteroidal anti-inflammatory drug therapy must continue beyond 20 weeks, and advises avoiding use after 28 weeks due to the additional risk of premature ductus arteriosus closure.

Correct Answer

C) Naproxen depletes the cytoprotective prostaglandins that maintain gastric mucosal integrity, creating a bleeding-prone ulcer, while warfarin prevents fibrin clot formation at the mucosal bleeding site — together producing a risk of hemorrhage greater than either drug alone

Rationale

This complication results from two parallel mechanisms acting at the same site. Naproxen suppresses cyclooxygenase-1-dependent prostaglandins in the gastric mucosa, removing the prostaglandin-dependent defense that normally maintains mucosal blood flow, mucus secretion, and epithelial repair — creating ulcers that bleed readily. At the same time, warfarin prevents fibrin clot formation at the bleeding site, converting a small mucosal bleed into a major hemorrhage. Naproxen does not inhibit vitamin K epoxide reductase and does not affect warfarin's pharmacokinetics to a clinically meaningful degree through protein binding displacement. When this combination cannot be avoided, proton pump inhibitor co-therapy is mandatory.

Correct Answer

A) Celecoxib does not inhibit cyclooxygenase-1 at therapeutic doses and therefore does not divert arachidonic acid into the lipoxygenase pathway, avoiding the leukotriene surge that triggers bronchoconstriction in patients with aspirin-exacerbated respiratory disease

Rationale

This patient's clinical profile — asthma combined with chronic rhinosinusitis and nasal polyps — is characteristic of aspirin-exacerbated respiratory disease. In these patients, inhibition of cyclooxygenase-1 diverts arachidonic acid into the lipoxygenase pathway, producing a surge of cysteinyl leukotrienes that triggers acute bronchoconstriction, rhinorrhea, and urticaria. Because any nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 can trigger this reaction, naproxen — a nonselective cyclooxygenase inhibitor — is contraindicated. Celecoxib inhibits cyclooxygenase-2 selectively and does not inhibit cyclooxygenase-1 at therapeutic doses; it therefore does not produce leukotriene shunting and is the preferred nonsteroidal anti-inflammatory drug in patients with confirmed or suspected aspirin-exacerbated respiratory disease.

Correct Answer

D) Ibuprofen suppresses prostaglandin E2 in the fetal circulation, causing premature constriction of the ductus arteriosus and fetal right ventricular pressure overload

Rationale

At 32 weeks of gestation the fetal ductus arteriosus — the vascular connection between the pulmonary artery and the aorta that allows blood to bypass the non-ventilated fetal lungs — depends on prostaglandin E2 for dilation. Ibuprofen inhibits cyclooxygenase and suppresses prostaglandin E2 synthesis in the fetal vasculature, allowing the ductus arteriosus to constrict prematurely. The result is increased pulmonary vascular resistance, right ventricular pressure overload, and potentially fetal right heart failure or hydrops. This risk is highest from 28 weeks onward and is the reason nonsteroidal anti-inflammatory drugs are strongly contraindicated in the third trimester. Option C (oligohydramnios from fetal renal dysfunction) is also a recognized risk of nonsteroidal anti-inflammatory drug use in pregnancy, but it is associated with use from 20 weeks onward, while premature ductal closure is the primary concern at 32 weeks.

Correct Answer

B) Topical diclofenac applied to the knee delivers drug locally to the target tissue with minimal systemic absorption, avoiding the gastrointestinal mucosal toxicity, renal prostaglandin suppression, and cardiovascular risks associated with systemic cyclooxygenase inhibition from oral ibuprofen

Rationale

The adverse effects of oral nonsteroidal anti-inflammatory drugs — gastrointestinal ulceration, renal prostaglandin suppression causing acute kidney injury, and cardiovascular risk — all result from systemic cyclooxygenase inhibition once the drug is absorbed into the bloodstream. This patient has three risk factors that make systemic nonsteroidal anti-inflammatory drug exposure particularly hazardous: a prior peptic ulcer, mild chronic kidney disease, and hypertension. Topical diclofenac gel applied to the knee delivers the drug directly to the target tissue through the skin, achieving effective local concentrations in the joint with minimal systemic absorption. The small fraction that does reach the systemic circulation is insufficient to produce clinically meaningful gastrointestinal, renal, or cardiovascular effects. This makes topical diclofenac the preferred formulation in elderly patients who need localized joint pain relief but cannot safely tolerate systemic nonsteroidal anti-inflammatory drug exposure.